InChI=1S/C24H26FNO4/c1- 15(2) 26- 21- 6- 4- 3- 5- 20(21) 24(16- 7- 9- 17(25) 10- 8- 16) 22(26) 12- 11- 18(27) 13- 19(28) 14- 23(29) 30/h3- 12,15,18- 19,27- 28H,13- 14H2,1- 2H3,(H,29,30) /b12- 11+/t18- ,19- /m0/s1 |
FJLGEFLZQAZZCD-JUFISIKESA-N |
C1(=CC=C(C=C1)C=2C=3C(N(C2/C=C/[C@@H](C[C@@H](CC(O)=O)O)O)C(C)C)=CC=CC3)F |
|
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor
An EC 3.4.24.* (metalloendopeptidase) inhibitor that interferes with the action of anthrax lethal factor endopeptidase (EC 3.4.24.83).
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
Any EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD+ or NADP+ acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme.
(via statin )
|
|
anticholesteremic drug
A substance used to lower plasma cholesterol levels.
(via statin )
|
|
View more via ChEBI Ontology
rac- (3R,5S,6E)- 7- [3- (4- fluorophenyl)- 1- (propan- 2- yl)- 1H- indol- 2- yl]- 3,5- dihydroxyhept- 6- enoic acid
|
fluvastatin
|
WHO MedNet
|
fluvastatina
|
WHO MedNet
|
fluvastatine
|
WHO MedNet
|
fluvastatinum
|
WHO MedNet
|
(±)-fluvastatin
|
ChEBI
|
(6E)- erythro7- [3- (4- fluorophenyl)- 1- (propan- 2- yl)- 1H- indol- 2- yl]- 3,5- dihydroxyhept- 6- enoic acid
|
ChEBI
|
erythro- (E)- 3,5- dihydroxy- 7- [3'- (4''- fluorophenyl)- 1'- (1''- methylethyl)indol- 2'- yl]hept- 6- enoic acid
|
ChEBI
|
rac-(3R,5S)-fluvastatin
|
ChEBI
|
rac- (3R,5S,6E)- 7- (3- (4- fluorophenyl)- 1- (1- methylethyl)- 1H- indol- 2- yl)- 3,5- dihydroxy- 6- heptenoic acid
|
ChEBI
|
9168031
|
Beilstein Registry Number
|
Beilstein
|
93957-54-1
|
CAS Registry Number
|
KEGG COMPOUND
|
93957-54-1
|
CAS Registry Number
|
ChemIDplus
|
|